Pegasys (pegylated interferon α -2a) / Ascletis, Roche  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pegasys (pegylated interferon α -2a) / Roche
ChiCTR-OPQ-14005299: Tolerance, pharmacokinetics and pharmacodynamics of PEG-INF-alpha 2b in healthly volunteers: A Randomized, Single center, drug control, Open-Label study

Recruiting
1
58
 
PegIntron subcutaneously ;PEGASYS subcutaneously ;hypodermic
West China Hospital, Sichuan University; West China Hospital, Sichuan University, ANHUI ANKE BIO TECNOLOGY(GROUP) CO.,LTD
Chronic hepatitis B and C
 
 
NCT06144697: A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

Recruiting
1
132
US
BMS-986465, Placebo, Pegasys, Famotidine
Bristol-Myers Squibb
Healthy Participants
03/25
03/25
NCT05729139: Cemiplimab/Peg-Interferon-α in Advanced CSCC

Withdrawn
1
21
US
Cemiplimab-Rwlc, Libtayo, PEG-IFN alfa-2a, PEGASYS
Baptist Health South Florida, Regeneron Pharmaceuticals
Cutaneous Squamous Cell Carcinoma, Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma
07/26
07/28

Download Options